A comparison of the efficacy and tolerability of the PCSK9 inhibitors, Alirocumab and evolocumab, in routine lipid clinic practice
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI